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INTRODUCTION
Experimental autoimmune encephalomyelitis (EAE) is
an organ specific autoimmune demyelinating disease of
the central nervous system (CNS). It can be induced in
susceptible animal strains either by active immunization
with CNS antigens or by passive transfer of encephalito-
genic cells into naive animals (for a review, see
P e n d e r , 1995). Experimental autoimune encephalo-
myelitis is a prototypical animal model of multiple scle-
rosis (MS), one of the most common chronic and disa-
bling disorders of the CNS in humans. However, al-
though distinct variants of EAE exist, no single model re-
flects all aspects of multiple sclerosis. Nevertheless, it is
still widely used as a model for this human disease on the
basis of clinical and histopathological resemblances (t , -
H a r t  and A m o r, 2003). The generally accepted con-
cept of pathogenesis in both EAE and MS suggests that
encephalitogenic proteins in the periphery activate mye-
lin-specific T cells, which cross the blood-brain barrier
(BBB) and migrate into the CNS. In CNS tissue, T lym-
phocytes are reactivated by autoantigens that cause ex-
pression of T-cell effector functions through the cytokine
network (L o c k et al. 2002), producing inflammation
and neurological defects (for a review, see W h e e l e r
and O w e n s, 2005). The histological characteristics of
EAE are infiltration of T-cells and macrophages into the
CNS, focal demyelization, and a variable degree of ax-
onal loss (B a u e r et al. 2001).
So far, current therapies of MS have limited effi-
ciency, and many new treatment protocols are currently
under trial (N e u h a u s et al. 2003). Based on its simi-
larities with MS, EAE might be helpful in preclinical
testing of various substances that could be considered for
treatment of this human CNS disease. 
Ribavirin (1-β-D-ribofuranosyl-1, 2, 4-triazole-3-
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carboxamide) and tiazofurin (2-β-D-ribofuranosylthia-
sole-4-carboxamide) are synthetic nucleoside analogs,
that act as inosine monophosphate dehydrogenase
(IMPDH) inhibitors through binding to the enzyme at
different sites. The active tiazofurin metabolite thiazole-
4-carboxamide adenine nucleotide (TAD) binds at the
NAD+/NADH ligand site on the enzyme molecule
(Y a m a d a et al. 1988), while the active ribavirin met-
abolite ribavirin monophosphate (RMP) binds at the
IMP/XMP ligand site (Y a m a d a et al. 1988), with
higher affinity than the natural substrates and products.
Inhibition of IMPDH, a rate–limiting enzyme in the de
novo purine synthesis pathway (W e b e r et al. 1997)
leads to depletion of the guanylate pools (F r a n c h e t -
t i and G r i f a n t i n i, 1999).  Reduction in guanine nu-
cleotide levels causes various disturbances in sensitive
cells such as inhibition of DNA/RNA and protein synthe-
sis (W e b e r et al. 2003), glycosilaton of adhesion mol-
ecules (S o k o l s k i and S a r t o r e l l i, 1985), inter-
ruption of signal transduction (W e b er et al. 2003; V a l -
l e e et al. 2000), etc. What is very important for MS and
EAE is that among other cell types, activated T lympho-
cytes are more sensitive to this IMPDH inhibition be-
cause salvage pathways for the production of guanine nu-
cleosides do not operate in them (A l l i s o n and E u -
g u i, 2000). This fact recommends ribavirin and tiazofur-
in as possible immunosuppressive/immunomodulatory
drugs. 
Recently it has been shown that each of these sub-
stances given preventively or therapeutically reduces
clinical symptoms of EAE in DA rats (S t o š i ć - G r u -
j i č i ć et al. 2002; M i l i ć e v i ć et al. 2003). More-
over, proceeding from the fact these drugs affect IMPDH
by different mechanisms, we previously showed that of
ribavirin and tiazofurin, given in combination preventive-
ly had a more potent effect in attenuating clinical and his-
tological symptoms of the disease (L a v r n j a et al.
2005). Accordingly the purpose of the present study was
to determine whether combined treatment with ribavirin
+ tiazofurin, starting precisely at the appearance of the
first clinical symptom, would have the same suppressing
effect on the development of EAE.
MATERIALS AND METHODS
Experimental animals
Male dark agouti (DA) rats, from 8 to 14 weeks of
age, were used throughout the experiments. The animals,
obtained from the animal colony maintained at the Siniša
Stanković Institute for Biological Research in Belgrade,
were divided into groups of 3-5 per cage, matched by age
and weight (150-220 g). Housed under conventional con-
ditions with laboratory food and water ad libitum, they
were watered by hand during the period of paralysis. The
experimental protocols were approved by the Local Ani-
mal Care Committee and conformed to the recommenda-
tions given by the National Research Council (1996).
Active induction and clinical evaluation of EAE
The rats were immunized by an encephalitogenic
emulsion prepared by mixing equal amounts of rat spinal
cord tissue homogenate (50% w/v in saline) and complete
Freund’s adjuvant containing 0.5 mg/ml Mycobacterium
tuberculosis (CFA, from Sigma, St. Louis, USA, or ICN
Pharmaceuticals, Costa Mesa, CA, USA). Each animal
was given 0.1 ml of the emulsion by a single intradermal
injection in the hind footpad. Immunized animals were
daily monitored for clinical symptoms of EAE, which
were graded on a scale of 1-5 as follows: (0) no clinical
symptoms; (1) flaccid tail; (2) hind limb paresis; (3) hind
limb paralysis; (4) moribund state; (5) death of the ani-
mal. Several parameters of the disease were examined to
evaluate the severity of EAE and the efficacy of thera-
peutic treatment with ribavirin and tiazofurin. These pa-
rameters were: incidence (the number of rats within a
group that developed a clinical score of 1 or greater in
comparison with the starting number of animals in the
group); daily mean clinical scores (the mean clinical
scores for all rats within a group on a given day); mean
maximal severity score (the mean of the maximal clinical
score that each rat in a group developed over the course
of the experiment); mean day to onset (the mean day on
which affected rats within a group first developed clini-
cal symptoms of the disease); and duration of paralysis
(the mean number of  days for which the rats had a score
of 3 or more). All animals were observed for 26 days aft-
er immunization. 
Treatment procedure
Ribavirin (1-β-D-ribofuranosyl-1,2,4-triazole-3-car-
boxamide) and tiazofurin (2-β-D-ribofuranosylthiazole-
4-carboxamide) were provided by ICN Pharmaceuticals
(Costa Mesa, CA). In order to analyze their therapeutic
effect on development of EAE, the immunized rats were
randomly divided in four groups: saline- (control), riba-
virin-treated, tiazofurin-treated and ribavirin + tiazofur-
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in-treated. The first group of treated animals received on-
ly ribavirin in a daily dosage of 30 mg/kg i. p.; the sec-
ond group received only tiazofurin in a dosage of 10
mg/kg i. p. every other day, and the third group was treat-
ed with a ribavirin + tiazofurin combination i. p. in a dos-
ages of 30 mg/kg/day and 10 mg/kg every other day, re-
spectively. Control EAE-immunized rats were given 0.2
ml/kg/day of saline i. p. In all groups, treatment started
when the first symptoms of EAE appeared (day 9 after
immunization) and lasted to the end of the observation
period (day 26 after immunization).
Statistical analysis
The results are expressed as mean ± SEM. Signifi-
cant differences in disease parameters were evaluated by
two-way ANOVA (daily mean clinical score, mean max-
imal severity score) and Student’s t-test (mean day to on-
set). Differences were considered statistically significant
at *p<0.05 and **p<0.005.
RESULTS
To analyze whether the nucleoside analogs ribavirin
and tiazofurin given solely or in combination can modu-
late the development of EAE, we used as a model the ac-
tively induced disease in highly susceptible DA rats. In
the control group, all immunized animals developed clin-
ical symptoms of the disease (incidence of 10/10 – Table
1), and the first symptoms were noticed on day 9 after im-
munization (Figs. 1A, B, and C). Disease symptoms in
this group reached a peak at day 14 (mean maximum se-
verity score was 2.5 ± 0.2, Table 1), recovery began at
day 16, and all animals completely recovered by days 23-
26 (Figs. 1A, B, C). Therapeutic treatment with ribavirin
and tiazofurin separately or in combination was initiated
from the onset of the first clinical symptoms of EAE. The
mean day of onset varied between days 10 and 14 (Table
1) after immunization. The ribavirin-treated group of an-
imals developed EAE at day 9 (Fig. 1A), but incidence of
the disease was lower compared with the control group of
animals (incidence of 3/7 – Table 1). In this experimental
group recovery began at day 15, and no clinical symptom
was noticeable in any of the animals after day 19 (Fig.
1A), meaning that duration of the disease was shortened
in comparison with the control rats. Ribavirin also con-
siderably ameliorated the severity of clinical symptoms
(mean maximum severity score - Table 1). The first signs
of EAE in the tiazofurin-treated group of animals were
spotted at day 11 (Fig. 1B), and the disease was devel-
oped in four out of seven animals (incidence – Table 1).
Therapeutic treatment with tiazofurin delayed the disease
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Table 1. Effect of in vivo treatment with ribavirin and tiazofurin on active EAE. 
† Parameters of disease were evaluated as described in Materials and methods. Data are presented as mean ± SEM
a Control EAE-immunized rats were given 0.1 ml saline  as a daily i.p. injection from the onset of the first clinical symptoms
b Daily i.p. injections of  30 mg/kg ribavirin  were given from the onset of the first clinical symptoms
c I.p. injections of  10 mg/kg tiazofurin  were given every other day from  the onset of the first clinical symptoms
d I.p. injections of  30 mg/kg/day ribavirin + 10 mg/kg/every other day tiazofurin  were given from  the onset of the first clinical symptoms
**P<0.005, *P<0.05 refers to control saline treated EAE rats (Student t-test).
           Treatment 
Parameters 
of disease† 
 
Saline a 
 
Ribavirin b 
 
Tiazofurin c 
Ribavirin d  
+ 
 tiazofurin 
Number of animals 10 7 7 6 
Incidence 10/10 
 
3/7 
 
4/7 
 
2/6 
 
Mean days to onset 
 
11.1 ± 0.6 11.3 ± 1.2 13.8 ± 1.0 13.0 ± 2.0 
Mean clinical score 0.4 ± 0.1 0.1 ± 0.04*  0.2 ± 0.1 0.1 ± 0.03* 
Duration of paralysis 0.8 ±  0.2  0 0.6 ± 0.6 0 
Mean maximum 
severity score 
2.5 ± 0.2 0.7 ± 0.4** 1.0 ±  0.4* 0.5 ± 0.3** 
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Fig. 1. Effect of ribavirin and tiazofurin treatment on supression of EAE clinical symptoms.
Ribavirin and tiazofurin suppress the course of EAE in DA rats. Daily mean clinical scores in rats treated with saline (control group -<-) and A: 30
mg/kg/day i.p. ribavirin (-r-) from the onset of the first EAE clinical symptoms to day 26; B: 10 mg/kg i.p.  tiazofurin (-£-) every other day from
the onset of the first EAE clinical symptoms to day 26; C: 30 mg/kg/day ribavirin + 10 mg/kg tiazofurin every other day (--) from the onset of the
first EAE clinical symptoms to day 26. Data points are presented as the mean ± SEM for 6-10 animals per group. **P < 0.005 and *P < 0.05 refers
to control saline treated EAE rats (two-way ANOVA).
peak for two days (Fig. 1B), and lowered the mean max-
imum severity score (Table 1). Furthermore, complete re-
covery was faster in tiazofurin-treated than in control an-
imals (at day 20, Fig. 1B). In the group treated with a
combination of ribavirin + tiazofurin, the first clinical
symptom of EAE was observed on day 11 (Fig. 1C), but
incidence of the disease was very low, only 2/6 (Table 1).
Treatment with ribavirin + tiazofurin significantly atten-
uated clinical symptoms of EAE compared to the control
(saline-treated) rats (the mean maximum severity score
was 0.5 ± 0.3 vs. 2.5 ± 0.2 in the control group, p<0.005,
Table 1) and accelerated recovery (no clinical symptoms
were detectable after day 19 following the immunization,
Fig. 1C). As indicators of ribavirin and tiazofurin effica-
cy in therapy of EAE, other parameters of disease sever-
ity were also followed, namely the duration of paralysis
(in days, Table 1) and the number of animals that devel-
oped this severe EAE symptom. Paralysis was noticed
only in the control group, in six out of 10 rats (duration
of paralysis was 0.8 ± 0.2 days, Table 1) and in the tiazo-
furin-treated animals, in one out of seven rats (duration of
paralysis was 0.6 ± 0.6 days, Table 1). In the other two
experimental groups of animals, ribavirin- and ribavirin +
tiazofurin-treated, no one animal developed this severe
EAE symptom (Table 1).
DISCUSSION
Therapeutic effects of the nucleoside analogs riba-
virin and tiazofurin given separately or in combination on
development of EAE were investigated in the present
study. We have shown that administration of these drugs
from the onset of first clinical symptoms of the disease
until the end of observation (at day 26 after immuniza-
tion) reduced its manifestation with different effective-
ness. The most pronounced effect was observed with the
ribavirin + tiazofurin combination.
The effect of nucleoside analogs on EAE was exam-
ined in DA rats, which are highly susceptible to EAE in-
duction (V u k m a n o v i ć et al. 1990), even without
any adjuvant (S t o š i ć - G r u j i č i ć et al. 2004) and
therefore represent an appropriate rodent model of exper-
imental autoimmunity of the CNS for studying novel
therapeutic strategies in MS.
Ribavirin was developed principally as an antiviral
drug (S i d w e l l et al. 1972; W i t k o w s k i et al.
1972) that is effective against a broad spectrum of
DNA/RNA viruses (T a m et al. 2001). On the other
hand, the efficacy of tiazofurin as an anticancer drug is
based on its antiproliferative and maturation-inducing ef-
fects, which have been demonstrated both in vitro and in
vivo (T i m a r et al. 1996; T o v a r i et al. 1996; W e -
b e r et al. 1996). The antiviral and anticancer effects of
these nucleoside analogs can be primarily ascribed to in-
hibition of IMPDH at different binding domains on the
enzyme molecule. As a result of the same mode of action,
ribavirin and tiazofurin may have an immunosuppres-
sive/immunomodulatory effect and thereby potential ap-
plication in the therapy of autoimmune diseases. Indeed,
an immunosuppressive effect of ribavirin was reported in
murine lupus nephritis (K l a s s e n et al. 1979) and in
the experimental autoreactive form of animal myocardi-
tis (M a i s c h et al. 1995). Also, in a previous study of
ours, we reported that ribavirin applied from the day of
EAE induction significantly reduced clinical symptoms,
lowered mononuclear cell infiltration, and prevented de-
myelination in the CNS (M i l i ć e v i ć et al. 2003). In
addition, we previously demonstrated that tiazofurin giv-
en continuously after EAE induction or following the on-
set of EAE symptoms, down-regulates severity of the dis-
ease (S t o š i ć - G r u j i č i ć et al. 2002). These find-
ings led us to investigate the effect of preventive treat-
ment with a combination of ribavirin and tiazofurin com-
bination applied immediately after EAE induction, but in
lower dosages than in the above mentioned studies
(L a v r n j a et al. 2005). The obtained results provided
evidence suggesting that a combination of these nucleo-
side analogs given in lower doses could be more effect-
ive in prevention of disease development than each drug
used alone. In the present study, we wanted to verify
whether combined treatment with ribavirin + tiazofurin
would suppress ongoing EAE if their application started
when clinical symptoms of the disease were clearly ex-
pressed (therapeutic treatment). We therefore initiated ad-
ministration of ribavirin and tiazofurin, separately and in
combination, from the onset of the first signs of EAE aft-
er induction. The results confirmed the beneficial effects
of ribavirin and tiazofurin in reducing all disease param-
eters. Again, the best effects were gained in the ribavirin
+ tiazofurin-treated group, especially in regard to EAE
incidence. To explain this observation, two facts must be
taken into consideration: 1. In the present study, animals
developed moderate EAE with variable beginning of
clinical symptoms between days 9 and 16 after immuni-
zation; and 2. We started with treatment when the onset
of EAE appeared in the first animal in all four groups.
Consequently, it is possible that ribavirin and tiazofurin
in some animals were given preventively, with the result
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that they completely prevented clinical manifestations of
EAE and caused a wide range of mean days to the onset
and very low incidence in all nucleoside analog-treated
groups, especially in the ribavirin + tiazofurin treated
group. These protective effects of ribavirin and tiazofur-
in might result from suppression of events associated
with activation of autoreactive T cells and their passing
through the BBB. On the molecular level, ribavirin and
tiazofurin act via their active metabolites, RMP and TAD,
respectively. The primary target of these active metabo-
lites is IMPDH, a key enzyme in the pathway of de novo
purine nucleotide synthesis (F r a n c h e t t i et al.
1996). Inhibition of IMPDH leads to depletion of the
guanylate and ATP pools, consequent impairment of spe-
cific signal transduction pathways, and blocking of de
novo DNA synthesis (W e b e r et al. 2003). While other
cell types can use purine synthesis salvage pathways, T
cells (including the CD4+ subpopulation of encephalito-
genic lymphocytes) completely depend on de novo pur-
ine synthesis (A l l i s o n and E u g u i , 2000). Addi-
tionally, it has been shown that ribavirin can arrest the
cell cycle in the G0/G1 phase (L i et al. 1999; V a l l e e
et al. 2000), induce cell differentiation, and cause sup-
pression growth (M a j u m d a r et al. 1995).  It is there-
fore possible that ribavirin and tiazofurin prevent the de-
velopment of EAE by inhibiting autoreactive T cell pro-
liferation.  However, such an effect is less likely, to judge
from a previous study of ours (S t o š i ć - G r u j i č i ć
et al. 2002.) showing that tiazofurin administration in vi-
vo did not inhibit the in vitro T cell proliferative response
to specific antigens or concanavalin A. As demonstrated
in the present study, ribavirin and tiazofurin also sup-
pressed clinicalsymptoms of EAE when their application
started in the effector phase of the disease after the ap-
pearance of the first clinical symptom, indicating that an-
other mechanism for mechanisms must also be taken in-
to account. Several lines of evidence suggest that interac-
tions between autoreactive T-cells and endothelial cells
of the BBB mediated by adhesion receptors and ligands
are of great importance in both the initiation and the ef-
fector phases of immune responses (A l l i s o n and
E u g u i , 2000). It has been shown that the depletion of
GTP by mycophenolic acid, which is the other known in-
hibitor of IMPDH, suppresses glycosylation and the
binding activity of adhesion molecules on lymphocytes
and monocytes (A l l i s o n et al. 1993; L a u r e n t et
al. 1996; A l l i s o n and E u g u i , 2000). This is con-
sistent with previous findings indicating that mononucle-
ar cells from tiazofurin-treated animals displayed a re-
duced capacity for intercellular adhesion or adhesion to
plastic (S t o š i ć - G r u j i č i ć et al. 2002). Thus, it is
possible that ribavirin and tiazofurin - as strong IMPDH
inhibitors - through GTP depletion and consequent limit-
ing of glycosylation of T cell adhesion molecules can ter-
minate further lymphocyte infiltration in the CNS. These
data suggest that suppression of adhesive cell-cell inter-
actions by ribavirin and tiazofurin might be a component
of the observed therapeutic action. In addition to their
ability to prevent the initial migration of T cells into the
CNS, they may also reduce the potential of T cells to elic-
it inflammation in the brain, which results in secondary
infiltration of macrophages and T cells.
In conclusion, the present study provides clear evi-
dence that lowered doses of ribavirin and tiazofurin giv-
en in combination can be more effective in suppression of
the ongoing disease, than each drug used alone. Our re-
sults point to synergistic/additive action of these two nu-
cleoside analogs. Also of great importance is their bene-
ficial effect in the late phase of the immune response,
which recommends them as suitable candidates for a new
approach in MS therapy.
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ТЕРАПИЈСКИ ЕФЕКАТ НУКЛЕОЗИДНИХ АНАЛОГА НА ЕКСПЕРИМЕНТАЛНИ
АУТОИМУНСКИ ЕНЦЕФАЛОМИЈЕЛИТИС КОД DARK AGOUTI ПАЦОВА
ДАНИЈЕЛА  СТОЈКОВ1, ИРЕНА ЛАВРЊА1, САЊА ШУБАШИЋ2, ИВАНА БЈЕЛОБАБА1, САЊА ПЕКОВИЋ1, ИВАНА ГАЂАНСКИ1,
МАРИЈА МОСТАРИЦА-СТОЈКОВИЋ3, СТАНИСЛАВА СТОШИЋ-ГРУЈИЧИЋ1, Љ. РАКИЋ4 и МИРЈАНА СТОЈИЉКОВИЋ1
1 Одељење за неуробиологију и имунологију, Институт за биолошка истраживања «Синиша
Станковић», Универзитет Београду, Булевар Деспота Стефана 142,
11060 Београд; Србија и Црна Гора
2 Биолошки факултет, Универзитет Београду, Студентски трг 3, 11000 Београд; Србија и Црна Гора
3 Институт за микробиологију и имунологију, Медицински факултет, Др Суботића 1,
11000 Београд; Србија и Црна Гора
4 Галеника а. д., 11000 Београд; Србија и Црна Гора
Експериментални аутоимунски енцефаломијели-
тис (ЕАЕ) је анимални модел који се обично кори-
сти као прототип хуманог неуролошког обољења –
мултипле склерозе. Циљ ове студије био је испити-
вање ефекта комбиноване терапије са два нуклео-
зидна аналога, рибавирина и тиазофурина, на ра-
звој ЕАЕ, активно изазваног код веома осетљивог
дарк агути соја пацова. Добијени резултати пока-
зали су да рибавирин и тиазофурин, примењени
појединачно или у комбинацији, од појаве првог
симптома ЕАЕ (терапијски третман), значајно
супримирају тежину ове болести. Међутим,
најбољи ефекти су постигнути комбинованим
третманом, што је вероватно последица синерги-
стичког или адитивног деловања рибавирина и ти-
азофурина.
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